Recombinant parathyroid hormone in the management of osteoporosis.
Compston
J
J
Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital Hills Road, Box 157, CB2 2QQ, Cambridge, UK. jec1001@cam.ac.uk
D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D004164:Diphosphonates / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000517:prevention & control*; D010281:Parathyroid Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D004164:Diphosphonates; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D011994:Recombinant Proteins